Uygun, V. Et Al. 2020. Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. PEDIATRIC BLOOD & CANCER , vol.67, no.4 .

Uygun, V., Karasu, G., Daloglu, H., Ozturkmen, S., Kilic, S. C., Yalcin, K., ... Celen, S. S.(2020). Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience. PEDIATRIC BLOOD & CANCER , vol.67, no.4.

Uygun, Vedat Et Al. "Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience," PEDIATRIC BLOOD & CANCER , vol.67, no.4, 2020

Uygun, Vedat Et Al. "Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience." PEDIATRIC BLOOD & CANCER , vol.67, no.4, 2020

Uygun, V. Et Al. (2020) . "Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience." PEDIATRIC BLOOD & CANCER , vol.67, no.4.

@article{article, author={Vedat Uygun Et Al. }, title={Ruxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience}, journal={PEDIATRIC BLOOD & CANCER}, year=2020}